MAP Pharmaceuticals (MAPP)
MAP Pharmaceuticals Profit Margin: -1736%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
MAPP Profit Margin Rankings
| Overall | 0th percentile | 4356 of 4397 |
| Sector | 6th percentile | 439 of 469 in Healthcare |
| Industry | 5th percentile | 35 of 37 in Drug Manufacturers - Other |
MAPP Profit Margin Range, Past 5 Years
| Minimum | -2867% | Mar 2011 |
| Maximum | 54.60% | Sep 2009 |
| Average | -909.4% |
About Profit Margin
Profit margin represents the percentage of revenue that a company keeps as profit after accounting for fixed and variable costs. It is calculated by dividing net income by revenue. The profit margin is mainly used for internal comparisons, because acceptable profit margins vary between industries. In general, narrow profit margins indicate increased volatility. For companies with significant fixed costs, wide profit margins reduce the risk that a decline in sales will cause a net profit loss.
Displayed as a percentage, profit margin can be thought as the amount of profit that a company keeps per dollar of revenue. For example, if a company has a profit margin of 43%, the company keeps $.43 of each dollar of revenue.
Learn More
You may also be interested in these MAPP related companies
MAPP News
$MAPP What's going on? Up 5.6% today. Anyone heard any news-meeting with FDA? Dredging the mire?
about 6 days ago by bampotscot
about 6 days ago by bampotscot
Listen to $MAPP at deutsche bank ag health care conference - live at 08:40 AM, ondemand after - http://stks.co/3iTo
about 23 days ago by earningscast
about 23 days ago by earningscast
$MAPP http://stks.co/3hmw Update of the chart, after the FDA CRL, keep bleeding breaking another resistance...
about 24 days ago by gantosj
about 24 days ago by gantosj
Canaccord Genuity Maintains a 'Buy' on MAP Pharmaceuticals (MAPP); Q1 EPS A Non-event; Focus Remains on LEVADEX
May 07, 9:12AM Street Insider
May 07, 9:12AM Street Insider
Robbins Umeda LLP Announces an Investigation of MAP Pharmaceuticals, Inc.
May 02, 5:33PM Business Wire
May 02, 5:33PM Business Wire
$PLX $RGEN $POZN $MAPP -major drug failure companies with hoghest short position for a reason $$
about 30 days ago by peterumble
about 30 days ago by peterumble
RT @stanleymandaley: Yes indeed. In your fantasy world. //BLOCKED REPORTED for Personal allegations, Grow Up $$ $VVUS $MAPP
about 32 days ago by peterumble
about 32 days ago by peterumble
RT @stanleymandaley Rumble who said $MAPP will head to 5s How's that working out //Made 30% on short n 120% on puts, Money Matters $VVUS $$
about 32 days ago by peterumble
about 32 days ago by peterumble
RT @stanleymandaley Rumble who said $MAPP will head to 5s How's that working out //Made 30% on short n 120% on puts, Money Matters #BURNING
about 32 days ago by peterumble
about 32 days ago by peterumble
I called the $MAPP like upage off lows and short cover this morn before 9 (see my tweet) shame I didn't really get in on it. maybe tomorrow?
about 34 days ago by epime7heus
about 34 days ago by epime7heus
$FURX already up from premarket lows will go up more as it gets bot here on over reaction for next catalyst & shorts cover just like $MAPP.
about 35 days ago by QR_Winner
about 35 days ago by QR_Winner
$PGNX will most likely bleed down like $MAPP over the next few weeks
about 35 days ago by VelocityTrader
about 35 days ago by VelocityTrader
RT @gantosj $MAPP http://stks.co/3SvP Keep the downtrend as expected, breaking down the $13.02 SL after 7 days heading to $10.54
about 38 days ago by chartly
about 38 days ago by chartly
$MAPP http://stks.co/3Soj Keep the downtrend as expected, breaking down the $13.02 SL after 7 days heading to $10.54
about 38 days ago by gantosj
about 38 days ago by gantosj
$MAPP have to wait 2 months to the FDA reply, then decision of calss 1 or 2 but it's most likely class2..that's a year waiting for 2nd PDUFA
about 48 days ago by gantosj
about 48 days ago by gantosj
$MAPP fair value 4$ only with no product and FDA rejection, big downside in the cards $$
about 49 days ago by johnrydar
about 49 days ago by johnrydar
MAP Pharmaceuticals, Inc. (MAPP) Reports Q4 Loss of 45c/Share; to Restate Interim Statements for First 3 Qtrs. of 2011
Mar 29, 7:03AM Street Insider
Mar 29, 7:03AM Street Insider
MAP Pharmaceuticals Reports 2011 Fourth Quarter and Year End Financial Results
Mar 29, 7:02AM Benzinga
Mar 29, 7:02AM Benzinga
UPDATE: Ladenburg Thalmann Reiterates Buy for Map Pharmaceuticals and $24 TP
Mar 28, 10:32AM Benzinga
Mar 28, 10:32AM Benzinga
Canaccord Genuity Reiterates a 'Buy' on MAP Pharmaceuticals (MAPP); CRL Disappointing, but Visibility Encouraging
Mar 28, 8:28AM Street Insider
Mar 28, 8:28AM Street Insider
Wall Street Maintains Positive Bias on MAP Pharmaceuticals (MAPP) Despite Levadex Setback
Mar 27, 8:58AM Street Insider
Mar 27, 8:58AM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| MAPP | 11.27 | -0.33 | -2.84% | 353.80M |
| MANT | 21.77 | -0.51 | -2.29% | 820.57M |
| MANH | 47.96 | -0.20 | -0.42% | 990.17M |
| MAN | 35.21 | -1.52 | -4.14% | 2.944B |
| MALL | 5.39 | -0.10 | -1.82% | 65.88M |
| MAIN | 23.26 | -0.22 | -0.94% | 633.26M |
| MAGS | 3.80 | -0.75 | -16.48% | 71.98M |
| MAG | 17.36 | -0.11 | -0.63% | 56.78M |
| MAC | 56.99 | -1.90 | -3.23% | 7.773B |
| NTL | 15.50 | -0.51 | -3.19% | 470.85M |